NECLIFE2026-01-012026-03-31NECLIFE2026-03-31NECLIFE2025-03-31NECLIFE2025-04-012026-03-31NECLIFE2026-01-012026-03-31in-capmkt:OtherExpenses1MemberNECLIFE2025-04-012026-03-31in-capmkt:OtherExpenses1MemberNECLIFE2026-03-31

OtherNoncurrentFinancialAssetsDomain1

NECLIFE2026-03-31

OtherNoncurrentAssetsDomain1

NECLIFE2026-03-31

OtherCurrentFinancialAssetsDomain1

NECLIFE2026-03-31

OtherCurrentAssetsDomain1

NECLIFE2026-03-31

OtherNoncurrentFinancialLiabilitiesDomain1

NECLIFE2026-03-31

OtherCurrentFinancialLiabilitiesDomain1

NECLIFE2026-03-31

OtherCurrentLiabilitiesDomain1

NECLIFE2026-01-012026-03-31

ItemsThatWillNotBeReclassifiedToProfitAndLoss1

NECLIFE2025-04-012026-03-31

ItemsThatWillNotBeReclassifiedToProfitAndLoss1

NECLIFE2026-01-012026-03-31

ItemsThatWillBeReclassifiedToProfitAndLoss1

NECLIFE2025-04-012026-03-31

ItemsThatWillBeReclassifiedToProfitAndLoss1

NECLIFE2026-01-012026-03-31

AuditorDomain1

iso4217:INRiso4217:INRxbrli:shares

532649

NECLIFE

NOTLISTED

INE023H01027

Nectar Lifesciences Limited

Main Board

Equity

2025-04-01

2026-03-31

2026-05-30

2026-05-25

INR

Lakhs

Quarterly

Fourth quarter

Single segment

Pharmaceutical Business Segment

2026-05-30

12:30:00

2026-05-30

14:20:00

true

Cash Flow Indirect

Declaration of unmodified opinion

2026-01-01

2026-03-31

Audited

Consolidated

75800000

12622000

59005000

828000

572631000

645086000

-569286000

-197164000

-372122000

-732058000

-424938000

-307120000

-679242000

793000

-678449000

194261000

-1.85

-1.53

-3.38

1. The above financial results were reviewed by Audit Committee on May 30, 2026, and approved by the Board of Directors (“Board”) in its meeting held on May 30, 2026, and Audited by the Statutory Auditors of the Company. The auditor's reports are attached along with these results. The Board hereby declares that audit reports do not contain any modified opinion. 2. The Company is exclusively in the pharmaceutical business segment. 3. The Statement of Assets and Liability is attached as Annexure 1. 4. The Statement of Cash Flow is attached as Annexure 2. 5. Previous period’s figures have been regrouped and reclassified wherever necessary to make them comparable with current period. 6. The figures of the last quarter for the current year and for the previous year are the balancing figures between the audited figure in respect of the full financial year ended March 31 and the unaudited published year to date figures upto the third quarter ended December 31 which was subject to limited review. 7. The Company has two wholly owned subsidiaries with the following details: - a) Neclife PT, Unipessoal LDA, remained inoperative during the year ended March 31, 2026. b) Avensis Exports Private Limited (“AEPL”), which was acquired effective March 6, 2026. 8. The Company is "Not a Large Corporate" as per the framework provided in the SEBI Circular dated October 19, 2023 on Fund raising by issuance of debt securities by Large Entities. 9. Going Concern During the year, the Company sold a substantial part of its existing business operations by way of slump sale and incurred losses. The transaction has resulted in significant liquidity, and the Company, after discharging all its debts, continues to possess adequate cash and liquid resources to meet its obligations, if any. Further, the Company has amended its object clause to undertake activities in the real estate sector and is currently evaluating the various projects under the revised business framework. In furtherance of this objective, the Company has also acquired AEPL as its wholly owned subsidiary. Considering the Company’s solvent financial position and availability of funds, the Board believes that the Company will continue to operate as a going concern for the foreseeable future. Accordingly, the financial results have been prepared on a going concern basis. 10. Material Transactions A. Discontinued Operations a. Pharma Business Pursuant to the Business Transfer Agreement (“BTA”) dated July 7, 2025, the Company transferred its Active Pharmaceutical Ingredients business located at Unit 1 and Unit 2, Derabassi, Punjab, and its Formulation business located at Unit 6, Baddi, Himachal Pradesh (collectively referred to as the “Pharma Businesses”) to Ceph Lifesciences Private Limited (“Ceph”) on a going concern basis through a slump sale, which was completed on November 10, 2025. The transaction was undertaken for an aggregate consideration of INR127,000.00 lakhs, which, after adjustments for working capital in accordance with the BTA, was finalized at a consolidated consideration of INR125,398.55 lakhs. Out of the above amount, the Company has received INR118,798.55 lakhs up to March 31, 2026, and the balance of INR6,600.00 lakhs is receivable as at the year end. A resultant profit of INR16,337.33 lakhs arising from the sale of the Pharma Businesses has been recognised under Exceptional Items. b. Menthol Assets Pursuant to the Asset Purchase Agreement (“APA”) dated July 7, 2025, the Company transferred the assets relating to its menthol business (“Menthol Assets”) to Ceph on November 10, 2025, for a consideration of INR2,000.00 lakhs, and received the entire consideration. B. Assets Classified as Held for Sale a. Capsule Business (EHGC) The Company has entered into a Business Transfer Agreement (“Capsule BTA”) dated December 20, 2025, with Capnest Health Care Private Limited (“Capnest”) for the slump sale of its Empty Hard Gelatin Capsule business located at Village Bhatoli Kalan, Pargana Dharmpur, Tehsil Baddi, District Solan, Himachal Pradesh (“Capsule Business”), on a going concern basis, for a consideration of INR1,990.00 lakhs, including transfer of related receivables and payables/creditors, subject to working capital adjustments specified in the Capsule BTA and approval under Section 118 of the Himachal Pradesh Tenancy and Land Reforms Act, 1972. The transaction shall be completed in accordance with the terms set out in the Capsule BTA. b. Other Assets The Company is also evaluating the monetization of the following assets with the objective of optimizing non-core assets and further strengthening its liquidity position: (i) Jammu Unit: Fixed assets pertaining to the Company’s Jammu unit, which has remained inoperative. Necessary steps in relation to the proposed transaction have been initiated. (ii) Land near Garhshankar, Punjab: Vacant land situated near Garhshankar, Punjab. A portion of the said land has already been sold subsequent to the financial year end, indicating progress in the Company’s planned disposal strategy. Accordingly, the results relating to the above disposed businesses/assets have been disclosed as discontinued operations in accordance with Ind AS 105. Further, in the audited standalone financial results, the net results of “Pharma Businesses”, “Menthol Assets” and “Capsule Business” has been disclosed separately as discontinued operation as required by Indian Accounting Standard (Ind AS) 105 – Asset Held for Sale and Discontinued Operations and Schedule Ill to the Companies Act, 2013. Consequently, the Company's Statement of Profit and Loss for the year ended March 31, 2026, pertains to its continuing operations only and for that purpose the results for the other reporting periods i.e., December 31, 2025, and March 31, 2026, have been restated accordingly. Standalone Operations relating to the "Pharma Businesses", "Menthol Assets" and “Capsule Business” in respect of total income, total expenses and tax are being disclosed separately as Discontinued operations as part of the results below: INR in lakhs S. No. Particulars Quarter Ended Year Ended 31-Mar-26 31-Dec-25 31-Mar-25 31-Mar-26 31-Mar-25 Audited Unaudited Audited Audited Audited 1 Revenue from operations 571.35 2,173.55 42,890.76 40,138.43 1,66,997.36 2 Other income 0.18 1,214.40 168.13 1,221.82 311.38 3 Total expenses 7,892.12 13,045.21 61,809.06 95,125.77 1,83,569.34 4 Profit before tax (7,320.58) (9,657.26) (18,750.17) (53,765.51) (16,260.60) 5 Exceptional item (Gain on slump sale) - 16,337.32 - 16,337.32 - 6 Tax expenses (4,249.38) 3,200.55 (5,751.87 (13,873.82) (4,822.78) 7 Net profit after tax (3,071.20) 3,479.51 (12,998.30 (23,554.37) (11,437.82) 11. Buy-back of Equity Shares Based on the Board’s approval at its meeting held on December 03, 2025, the Company undertook a buy-back of up to 3,00,00,000 fully paid-up equity shares of INR1 each at INR27.00 per share, aggregating INR8,100.00 lakhs, representing approximately 13.38% of the Company’s paid-up equity share capital as at March 31, 2025, through the tender offer route on a proportionate basis from eligible equity shareholders, excluding the Promoters and Promoter Group, in accordance with Sections 68, 69 and 70 of the Companies Act, 2013 (“Act”) and the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended. The buy-back was open from December 31, 2025 to January 06, 2026. The consideration was paid by the Company on January 13, 2026, and the 3,00,00,000 equity shares were extinguished by the National Securities Depository Limited on January 20, 2026. Consequent to the buy-back, the paid-up equity share capital of the Company was reduced by INR300.00 lakhs, with the premium of INR7,800.00 lakhs adjusted against the Securities Premium Account and INR300.00 lakhs transferred to the Capital Redemption Reserve in accordance with Section 69 of the Companies Act, 2013. 12. Pursuant to the approvals granted by the Board, the Company deployed certain surplus funds in mutual fund, ETF and equity instruments during the year. Subsequently, volatility in the financial markets arising from prevailing market conditions and geopolitical developments adversely impacted the value of such investments, resulting in a loss of INR 5,209.53 lakhs. The resultant impact has been recognized in the Statement of Profit and Loss in accordance with Ind AS 109 – Financial Instruments. 13. Extraordinary and Exceptional items – Refer Note 10.

2025-04-01

2026-03-31

Audited

Consolidated

92909000

19122000

361252000

3426000

587898000

971698000

-878789000

-305316000

-573473000

-3742819000

-1387382000

-2355437000

-2928910000

794000

-2928116000

194261000

-2.62

-10.78

-13.4

Other Expenses

572631000

Other Expenses

587898000

1034049000

11124000

2351000

700000

29284000

32335000

2244776000

5558000

3327842000

2982000

129708000

1121348000

913000

659999000

1911968000

614733000

2529683000

358539000

6216064000

194261000

5628693000

5822954000

91917000

49000

91966000

257123000

3308000

71000

260502000

40642000

393110000

6216064000

Other non-current financial assets

29284000

Other non-current assets

5558000

Other current financial assets

659999000

Other current assets

614733000

Other non-current financial liabilities

91917000

Other current financial liabilities

257123000

Other current liabilities

3308000

361252000

2329244000

166461000

2993086000

1122020000

16177000

7988000

-566518000

-3417037000

-80964000

-7208000

228031000

-29150000

-185907000

-503760000

4000

70398000

2037293000

-7009062000

-2608456000

-3487245000

204576000

122742000

3344116000

3989489000

4000

70398000

12574626000

12081489000

810000000

6487534000

6326000

361252000

-7665112000

929132000

192216000

1121348000

Remeasurement of the net defined benefit liability/asset

1218000

Remeasurement of the net defined benefit liability/asset

1218000

426000

Foreign Exchange Translation Reserve (Net of Tax)

2000

Foreign Exchange Translation Reserve (Net of Tax)

3000

1000

793000

794000

Audited

true

Deepak Jindal & Co.

true

2027-05-31